CytomX Therapeutics Inc. (NASDAQ:CTMX) finished Friday with an addition of $0.23 to close at $5.34, an upside of 4.50 percent. An average of 399,480 shares of common stock have been traded in the last five days. There was a gain of $0.20 in the past week, and it reached a new high 20 times over the past 12 months. The last 20 days have seen an average of 346,850 shares traded, while the 50-day average volume stands at 527,272.
CTMX stock has decreased by -1.84% in the last month. The company shares reached their 1-month lowest point of $4.76 on 10/06/21. With the stock rallying to its 52-week high on 04/28/21, shares of the company touched a low of $4.28 and a high of $10.05 in 52 weeks. It has reached a new high 19 times so far this year and lost -18.47% or -$1.21 in price. In spite of this, the price is down -46.87% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
129 days have passed since CytomX Therapeutics Inc. (CTMX) last reported insider trading activity. McCarthy Sean A., who is President and CEO, most recently acquired $100,000 shares at $7.04 per share on Jun 16. In this transaction, the insider spent $704,470. President and CEO, McCarthy Sean A., disposed of 100,000 shares at a price of $7.49 on Mar 31. The insider now owns more than $749,470 worth of shares.
CytomX Therapeutics Inc. (CTMX) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 33.43 for the sector. The stock’s beta is 0.64. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 5.29, the price-to-book (PB) ratio at 2.66.
The quick ratio of CytomX Therapeutics Inc. for the three months ended June 29 was 2.90, and the current ratio was 2.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. CytomX Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -42.99%, while its operating margin for the same period stands at -97.00%. Its gross profit as reported stood at $148.97 million compared to revenue of $100.36 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, CytomX Therapeutics Inc.’s return on assets was -16.40%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, CytomX Therapeutics Inc. had $10.03 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$19.24 million in the quarter, while revenues of -$15.55 million were grew 18.5%. The analyst consensus anticipated CytomX Therapeutics Inc.’s latest quarter earnings to come in at -$0.32 per share, but it turned out to be -$0.3, a 6.30% surprise. For the quarter, EBITDA amounted to -$18.39 million. Shareholders own equity worth $65.16 million.
From a technical analysis perspective, let’s take a brief look at CytomX Therapeutics Inc. (CTMX) price momentum. RSI 9-day as of the close on 22 October was 65.58%, suggesting the stock is Neutral, with historical volatility in this time frame at 31.57%.
As of today, CTMX’s price is $5.11 +3.89% or $0.20 from its 5-day moving average. CTMX is currently trading +1.52% higher than its 20-day SMA and -20.54% lower than its 100-day SMA. However, the stock’s current price level is +7.88% above the SMA50 and -25.73% below the SMA200.
The stochastic %K and %D were 75.36% and 63.68%, respectively, and the average true range (ATR) was 0.19. With the 14-day stochastic at 96.67% and the average true range at 0.20, the RSI (14) stands at 58.74%. The stock has reached 0.05 on the 9-day MACD Oscillator while the 14-day reading was at 0.13.
Barclays downgraded CytomX Therapeutics Inc. (NASDAQ: CTMX) to a an Underweight rating in its most recent analyst report. Previously, the stock was rated as an Equal weight. The consensus rating for CytomX Therapeutics Inc. (CTMX) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell CTMX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is CTMX’s price target for the next 12 months?
Analysts predict a range of price targets between $7.00 and $18.00, with a median target of $13.00. Taking a look at these predictions, the average price target given by analysts for CytomX Therapeutics Inc. (CTMX) stock is $13.14.